Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized Trial of the Safety of Dymista Nasal Spray and Fluticasone Propionate Nasal Spray in Children Ages >4 Years to <12 Years With Allergic Rhinitis.

Trial Profile

Randomized Trial of the Safety of Dymista Nasal Spray and Fluticasone Propionate Nasal Spray in Children Ages >4 Years to <12 Years With Allergic Rhinitis.

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Mar 2017

At a glance

  • Drugs Azelastine/fluticasone-propionate (Primary) ; Fluticasone propionate
  • Indications Allergic rhinitis
  • Focus Adverse reactions
  • Sponsors Meda Pharmaceuticals
  • Most Recent Events

    • 06 Mar 2017 Efficacy results presented at the 2017 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
    • 20 Feb 2015 Dymista [Azelastine/fluticasone propionate] was approved by US FDA for children aged 6-11 years based on the data from this and another phase III trial, as per MEDA media release.
    • 25 Mar 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top